Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Cencora, Inc. Common Stock
(NY:
COR
)
360.85
+0.88 (+0.24%)
Streaming Delayed Price
Updated: 3:55 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cencora, Inc. Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Peering Into Cencora's Recent Short Interest
↗
February 01, 2024
Via
Benzinga
Drug Wholesale Firm Cencora Starts 2024 With Strong Growth, Lifts Annual Forecast On Commercial COVID-19 Vaccine Distribution
↗
January 31, 2024
Cencora reports Q1 2024 results with adjusted EPS at $3.28 and revenue of $72.3 billion. Explore the company's fiscal year 2024 guidance and growth projections.
Via
Benzinga
Cencora Reports Fiscal 2024 First Quarter Results
January 31, 2024
From
Cencora
Via
Business Wire
Chart Of The Day: Cencora - Name Changed To Protect The Innocent?
↗
January 17, 2024
Cencora, Inc. sources and distributes pharmaceutical products.
Via
Talk Markets
Is AI More Valuable In Advertising Than Healthcare? Jim Cramer Questions Wall Street's Preference
↗
January 10, 2024
Cramer shared his insights during his attendance at JPMorgan's healthcare conference,
Via
Benzinga
Topics
Artificial Intelligence
Here's How Much You Would Have Made Owning Cencora Stock In The Last 20 Years
↗
January 05, 2024
Via
Benzinga
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
↗
December 18, 2023
Via
Benzinga
Here's How Much You Would Have Made Owning Cencora Stock In The Last 15 Years
↗
December 06, 2023
Via
Benzinga
Earnings Scheduled For January 31, 2024
↗
January 31, 2024
Companies Reporting Before The Bell • Novartis (NYSE:NVS) is likely to report quarterly earnings at $1.68 per share on revenue of $11.56 billion.
Via
Benzinga
How Is The Market Feeling About Cencora?
↗
January 11, 2024
Via
Benzinga
(COR) - Analyzing Cencora's Short Interest
↗
December 05, 2023
Via
Benzinga
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
January 04, 2024
From
Cencora
Via
Business Wire
This 1 Surprising New Tailwind Is Lifting These 2 Evergreen Stocks
↗
December 04, 2023
New growth drivers are helping to propel these reliable and steady businesses.
Via
The Motley Fool
Jim Cramer: Buy Shares Of This Personal Computer Giant, Wait For 'A Little Bit Of Pullback'
↗
November 29, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he would not buy CRISPR Therapeutics AG (NASDAQ: CRSP) stock "all the way up here.
Via
Benzinga
Teva Pharma is the way to play the re-rise of generic drugs
November 28, 2023
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth
Via
MarketBeat
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,300 Today
↗
November 21, 2023
Via
Benzinga
How Is The Market Feeling About Cencora?
↗
November 17, 2023
Via
Benzinga
Here's How Much $1000 Invested In Cencora 5 Years Ago Would Be Worth Today
↗
October 31, 2023
Via
Benzinga
3 Biotech Stocks You’ll Regret Not Buying Soon: November 2023
↗
November 14, 2023
The global biotechnology market could nearly triple by 2030. Investors should consider buying these biotech stocks before they explode.
Via
InvestorPlace
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
November 09, 2023
From
Cencora
Via
Business Wire
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
↗
November 03, 2023
Bulls are back in control as the major indexes confirmed the uptrend this week.
Via
Investor's Business Daily
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $12,000 Today
↗
October 18, 2023
Via
Benzinga
Peering Into Cencora's Recent Short Interest
↗
October 17, 2023
Via
Benzinga
Peering Into Cencora's Recent Short Interest
↗
September 29, 2023
Via
Benzinga
Obesity And Diabetes Drugs Demand Help Distributor Cencora Propel Revenue In Q3
↗
November 02, 2023
Cencora Inc's (NYSE: COR), formerly AmerisourceBergen Corporation,
Via
Benzinga
Cencora Reports Fiscal 2023 Fourth Quarter and Year End Results
November 02, 2023
From
Cencora
Via
Business Wire
Earnings Due For Stealth GLP-1 Weight-Loss Drug Play McKesson, Rivals
↗
November 01, 2023
McKesson earnings are on tap, with Cencora and Cardinal Health due soon.
Via
Investor's Business Daily
Eli Lilly, McKesson, Novartis Flash Promising Chart Action
October 09, 2023
Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.
Via
MarketBeat
$100 Invested In Cencora 20 Years Ago Would Be Worth This Much Today
↗
September 27, 2023
Via
Benzinga
Cencora, Formerly AmerisourceBergen, Announces Date and Time for Fourth Quarter Fiscal 2023 Earnings Release
October 02, 2023
From
Cencora
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
